StockData
NewAmsterdam Pharma Co N.V. logo

NewAmsterdam Pharma Co N.V. (NAMS) company profile

NAMSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NAMSW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$19.39−0.07 (-0.36%)

Close on Nov 17, 2026Market cap $2.32BP/E –Yield –

About NewAmsterdam Pharma

Pharmaceutical Preparations, SIC 2834

This late-stage biopharmaceutical company focuses on developing therapies for cardiometabolic disorders in patient groups with inadequate or poorly tolerated existing treatment options. Its primary candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein inhibitor investigated as a once-daily monotherapy or in a fixed-dose combination with ezetimibe. These investigational therapies serve as adjuncts to statin regimens to lower low-density lipoprotein cholesterol in individuals at risk of cardiovascular disease, atherosclerotic cardiovascular disease, and heterozygous familial hypercholesterolemia.

The company operates without commercial retail locations or operational store facilities, as its pipeline remains under clinical evaluation. Clinical research programs encompass studies conducted across multiple international regions, including the United States, Europe, Japan, and China, with pivotal trials enrolling thousands of participants globally. Commercialization and licensing rights are established in European countries via a third-party partnership, while United States rights remain retained internally. The text does not state the company's headquarters location.

Summary of the business section of NewAmsterdam Pharma's latest annual report, written by StockData.

Company profile

Company

Legal name
NewAmsterdam Pharma Co N.V.
Headquarters
Narrden, P7
Address
Gooimeer 2-35 1411 DC
Phone
35 206 2971
Employees
100, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
P7
Fiscal year ends
December 31
Auditor
Deloitte Accountants B.V, Eindhoven, The Netherlands

Stock & identifiers

Ticker
NAMS
Other tickers
NAMSW
Exchange
Nasdaq
IPO date
Feb 9, 2021
Shares outstanding
120M, Aug 3, 2026
Public float
$1.35B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1936258
FIGI
BBG01BNNTQN4
Share class FIGI
BBG01BNNTQP2
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Johannes Jacob Pieter KasteleinChief Scientific Officer, Director122,802
Michael H. DavidsonChief Executive Officer, Director1,078,638
Robert William GunningVice President, Controller3,200
Louise Frederika KooijChief Accounting Officer49,353
Mayur Ian SomaiyaChief Financial Officer98,166
Douglas F. KlingChief Operating Officer44,000
Michael F. Marino IIISee Remarks55,000
Juliette Berangere AudetSee Remarks15,104
William A. Jones JrChief Commercial Officer43,000
John W. SmitherDirector8,760
Louis G. LangeDirector10,806
der Kamp Hilde Johanna vanDirector10,360
William LewisDirector10,360
Mark C. McKennaDirector10,360
Adele M. GulfoDirector14,260
James N. TopperDirector6,829,524

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$13.64M$30.50M$4.30M$322$135
FY2024$6.47M$49.55M$2.59M$236$104
FY2023$5.81M$4.72M$3.27M$102$105

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Michael Davidson, M.D.
Chief Executive Officer
$646.15K$3.57M$8.93M$474.92K$18.07K$13.64M+111%
Ian Somaiya
Chief Financial Officer
$486.72K$986.48K$2.94M$269.67K$14.00K$4.70M+275%
Louise Kooij
Chief Accounting Officer
$452.22K$470.80K$1.07M$220.46K$22.75K$2.24M–
John Kastelein, M.D., Ph.D. FESC
Chief Scientific Officer
$537.87K$1.33M$2.67M$270.28K–$4.81M+42%
Douglas Kling
Chief Operating Officer
$519.97K$1.31M$3.34M$256.08K$14.00K$5.44M+111%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 100 employees, consisting of clinical, research and development, business development, regulatory, finance and operational personnel.”

Corporate history

Events identified from SEC filings

DateEventDetails
Nov 22, 2022ListingRegistration of securities on an exchange (Form 8-A)
Nov 22, 2022Name changeName changed from NewAmsterdam Pharma Co B.V. to NewAmsterdam Pharma Co N.V.
Nov 18, 2022ListingRegistration of securities on an exchange (Form 8-A)
Aug 4, 2022MergerRegistration of securities for a merger or exchange offer (S-4)

See a number that looks wrong?